Rhelion Life Sciences Corp. (CSE:RHEL)
Canada · Delayed Price · Currency is CAD 0.0250
-0.0050 (-16.67%)
Aug 28, 2026, 3:12 PM EST
Rhelion Life Sciences Revenue
In the fiscal year ending March 31, 2026, Rhelion Life Sciences had annual revenue of 4.20M CAD, down -15.15%. Rhelion Life Sciences had revenue of 875.32K in the quarter ending March 31, 2026, with 3.05% growth.
Revenue
4.20M
Revenue Growth
-15.15%
P/S Ratio
3.66
Revenue / Employee
n/a
Employees
n/a
Market Cap
15.35M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 4.20M | -749.01K | -15.15% |
| Mar 31, 2025 | 4.94M | 192.40K | 4.05% |
| Mar 31, 2024 | 4.75M | 802.31K | 20.31% |
| Mar 31, 2023 | 3.95M | 1.62M | 69.84% |
| Mar 31, 2022 | 2.33M | 2.21M | 1,995.96% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Ayr Wellness | 650.97M |
| FLUENT | 107.89M |
| GoGo AI Network | 3.98M |
| HYTN Innovations | 2.80M |
| Sharc International Systems | 1.94M |
Rhelion Life Sciences News
- 3 days ago - Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Issued New United States Patent, Extending the Broadest Natural Psilocybin Patent Estate - Newsfile Corp
- 5 days ago - Rhelion Life Sciences Wholly Owned Subsidiary Filament Health Completes Shipment of PEX010 for University of Washington Phase 2a Trial in Cancer-Related Anxiety and Depression - Newsfile Corp
- 10 days ago - Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Letter of Intent with Darmiyan, Inc. to Explore Use of FDA De Novo Authorized BrainSee(R) AI Platform in Early Alzheimer's Disease Trial Design - Newsfile Corp
- 11 days ago - Rhelion Life Sciences Announces Appointment of Samiuddin Khaja as CFO - Newsfile Corp
- 16 days ago - Rhelion Life Sciences Signs Agreement with University Health Network for Randomized Clinical Trial of Psilocybin in Parkinson's Disease Depression - Newsfile Corp
- 26 days ago - Rhelion Life Sciences Corp. Commences Trading Under New Name and Ticker Symbol RHEL on the CSE - Newsfile Corp
- 4 weeks ago - Red Light Holland Reports Fiscal 2026 Audited Year-End Results and Provides Update on Rhelion Life Sciences - Newsfile Corp
- 6 weeks ago - Red Light Holland Announces Corporate Rebrand to Rhelion Life Sciences Corp - Newsfile Corp